Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04906746 · ClinicalTrials.gov registry record · Early Phase 1
Ruxolitinib for Cancer Cachexia
A Early Phase 1 study of Stage IV Non-small Cell Lung Cancer and Cachexia, sponsored by Tu Dan.
- Active
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT04906746 is a Early Phase 1 study of Stage IV Non-small Cell Lung Cancer and Cachexia that is active but no longer recruiting, run by Tu Dan. The registered enrollment target is 10 participants, below the 689-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04906746, a Early Phase 1 study of Stage IV Non-small Cell Lung Cancer and Cachexia, is active but no longer recruiting, sponsored by Tu Dan.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess toxicity with use of Ruxolitinib in NSCLC cachexia patients; to associate levels of JAK/STAT signaling in blood, adipose, and muscle pre- and post-ruxolitinib treatment with changes in cachexia and anorexia.
Conditions Studied
Interventions
- DRUG Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients.
Study Locations (1)
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-02-23 |
| Est. Completion | 2025-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04906746
The ClinicalTrials.gov registry entry for NCT04906746 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 689-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Tu Dan, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Stage IV Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients. is the first listed.
NCT04906746 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04906746 about?
NCT04906746 is a clinical study titled "Ruxolitinib for Cancer Cachexia". To assess toxicity with use of Ruxolitinib in NSCLC cachexia patients; to associate levels of JAK/STAT signaling in blood, adipose, and muscle pre- and post-ruxolitinib treatment with changes in cachexia and anorexia.
What is the current status of trial NCT04906746?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2022-02-23. Estimated completion is 2025-12.
What conditions does trial NCT04906746 study?
This clinical trial studies the following conditions: Stage IV Non-small Cell Lung Cancer, Cachexia.
What interventions are being tested in trial NCT04906746?
The interventions under investigation include: Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients. (DRUG).
Who is sponsoring clinical trial NCT04906746?
This trial is sponsored by Tu Dan, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04906746 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Non-small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
COMPLETED · Early Phase 1
-
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RECRUITING · Phase 1
-
Patient-centered, Optimal Integration of Survivorship and Palliative Care
RECRUITING · NA
-
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
RECRUITING · NA
-
Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer
RECRUITING · NA
-
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.